MA29570B1 - Procede pour le traitement des tumeurs du cerveau a l'aide d'anticorps - Google Patents
Procede pour le traitement des tumeurs du cerveau a l'aide d'anticorpsInfo
- Publication number
- MA29570B1 MA29570B1 MA30523A MA30523A MA29570B1 MA 29570 B1 MA29570 B1 MA 29570B1 MA 30523 A MA30523 A MA 30523A MA 30523 A MA30523 A MA 30523A MA 29570 B1 MA29570 B1 MA 29570B1
- Authority
- MA
- Morocco
- Prior art keywords
- brain tumors
- antibodies
- treatment
- patient
- monoclonal antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention porte sur une méthode de traitement des tumeurs du cerveau d'un patient par administration systémique d'un anticorps monoclonal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68711805P | 2005-06-02 | 2005-06-02 | |
| US75109205P | 2005-12-15 | 2005-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29570B1 true MA29570B1 (fr) | 2008-06-02 |
Family
ID=37482322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30523A MA29570B1 (fr) | 2005-06-02 | 2007-12-27 | Procede pour le traitement des tumeurs du cerveau a l'aide d'anticorps |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20070036797A1 (fr) |
| EP (1) | EP1885400A4 (fr) |
| JP (2) | JP2008545753A (fr) |
| KR (1) | KR20080026562A (fr) |
| AU (1) | AU2006252419B2 (fr) |
| BR (1) | BRPI0611009A2 (fr) |
| CA (1) | CA2607699A1 (fr) |
| CR (1) | CR9512A (fr) |
| IL (1) | IL187318A0 (fr) |
| MA (1) | MA29570B1 (fr) |
| MX (1) | MX2007015056A (fr) |
| NO (1) | NO20080012L (fr) |
| RU (1) | RU2007146986A (fr) |
| WO (1) | WO2006130773A2 (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| EP1934261B1 (fr) * | 2005-09-26 | 2014-10-29 | Medarex, L.L.C. | Anticorps monoclonaux humains diriges contre cd70 |
| AR059922A1 (es) | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| MX2008015138A (es) | 2006-06-02 | 2009-01-28 | Aveo Pharmaceuticals Inc | Proteinas de union al factor de crecimiento de hepatocitos (fch). |
| US7649083B2 (en) | 2006-06-02 | 2010-01-19 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding antibody |
| HRP20160082T1 (hr) | 2006-09-29 | 2016-02-26 | Oncomed Pharmaceuticals, Inc. | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka |
| US20100150950A1 (en) * | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| BRPI0816142A2 (pt) * | 2007-08-24 | 2015-02-18 | Novartis Ag | Modulador de nrg1 para tratamento de distúrbios respiratórios. |
| TW200948380A (en) * | 2008-04-11 | 2009-12-01 | Galaxy Biotech Llc | Combination of HGF inhibitor and PTEN agonist to treat cancer |
| US20110217294A1 (en) * | 2008-04-11 | 2011-09-08 | Daniel Fults | Combination of hgf inhibitor and hedgehog inhibitor to treat cancer |
| KR101590495B1 (ko) * | 2008-05-29 | 2016-02-01 | 갤럭시 바이오테크, 엘엘씨 | 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체 |
| WO2010119991A2 (fr) | 2009-04-17 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Nouveau procédé de traitement anticancéreux |
| EP3485908B1 (fr) | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Combinaison thérapeutique et utilisation d'anticorps antagonistes de dll4 et d'agents anti-hypertenseurs |
| ES2519348T3 (es) * | 2010-02-18 | 2014-11-06 | Genentech, Inc. | Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer |
| RU2439160C1 (ru) * | 2010-06-25 | 2012-01-10 | Государственное общеобразовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) | Способ получения моноклональных антител к аблюминальному мембранному антигену церебральных эндотелиоцитов |
| EP2588107A1 (fr) * | 2010-07-01 | 2013-05-08 | Takeda Pharmaceutical Company Limited | Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9783601B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| TWI583699B (zh) | 2011-09-23 | 2017-05-21 | 安可美德藥物股份有限公司 | Vegf/dll4結合劑類及彼等之用途 |
| CA2889638A1 (fr) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methodes et surveillance d'un traitement par un antagoniste de dll4 |
| EP3212233B1 (fr) | 2014-10-31 | 2020-06-24 | Oncomed Pharmaceuticals, Inc. | Thérapie combinée pour le traitement d'une maladie |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2564486B2 (ja) * | 1986-07-14 | 1996-12-18 | 修治 橋本 | 肝細胞増殖因子 |
| US5837676A (en) * | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
| US6498144B1 (en) * | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
| US5707624A (en) * | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
| US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| US5646036A (en) * | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| ATE465257T1 (de) * | 1996-07-03 | 2010-05-15 | Genentech Inc | Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen |
| WO2004019991A2 (fr) * | 2002-08-30 | 2004-03-11 | F. Hoffmann-La Roche Ag | Antagoniste nk4 du facteur de croissance de l'hepatocyte/du facteur de dispersion pour le traitement de gliome |
| US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| US7220410B2 (en) * | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
| EA015363B1 (ru) * | 2003-07-18 | 2011-06-30 | Эмджен Инк. | Агенты, специфически связывающие фактор роста гепатоцитов, и их применение |
| EP2210607B1 (fr) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(méthyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phényl]-N'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide pour le traitement du cancer |
| CA2572331A1 (fr) * | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | Modulateurs de c-met et leur methode d'utilisation |
| WO2007056523A2 (fr) * | 2005-11-08 | 2007-05-18 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Procedes de diagnostic et de surveillance de la progression d'un cancer |
| AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| US20110217294A1 (en) * | 2008-04-11 | 2011-09-08 | Daniel Fults | Combination of hgf inhibitor and hedgehog inhibitor to treat cancer |
| PE20091827A1 (es) * | 2008-04-11 | 2009-11-20 | Galaxy Biotech Llc | Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer |
-
2006
- 2006-06-01 RU RU2007146986/14A patent/RU2007146986A/ru not_active Application Discontinuation
- 2006-06-01 EP EP06771847A patent/EP1885400A4/fr not_active Withdrawn
- 2006-06-01 AU AU2006252419A patent/AU2006252419B2/en not_active Ceased
- 2006-06-01 WO PCT/US2006/021293 patent/WO2006130773A2/fr not_active Ceased
- 2006-06-01 BR BRPI0611009-6A patent/BRPI0611009A2/pt not_active IP Right Cessation
- 2006-06-01 US US11/446,045 patent/US20070036797A1/en not_active Abandoned
- 2006-06-01 CA CA002607699A patent/CA2607699A1/fr not_active Abandoned
- 2006-06-01 MX MX2007015056A patent/MX2007015056A/es not_active Application Discontinuation
- 2006-06-01 KR KR1020077030521A patent/KR20080026562A/ko not_active Withdrawn
- 2006-06-01 JP JP2008514858A patent/JP2008545753A/ja active Pending
-
2007
- 2007-11-12 IL IL187318A patent/IL187318A0/en unknown
- 2007-11-12 CR CR9512A patent/CR9512A/es not_active Application Discontinuation
- 2007-12-27 MA MA30523A patent/MA29570B1/fr unknown
-
2008
- 2008-01-02 NO NO20080012A patent/NO20080012L/no not_active Application Discontinuation
-
2010
- 2010-01-19 US US12/690,045 patent/US20100221250A1/en not_active Abandoned
-
2013
- 2013-01-10 JP JP2013002317A patent/JP2013136580A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013136580A (ja) | 2013-07-11 |
| EP1885400A2 (fr) | 2008-02-13 |
| NO20080012L (no) | 2008-02-20 |
| BRPI0611009A2 (pt) | 2010-08-10 |
| EP1885400A4 (fr) | 2011-01-26 |
| WO2006130773A2 (fr) | 2006-12-07 |
| WO2006130773A3 (fr) | 2009-04-16 |
| JP2008545753A (ja) | 2008-12-18 |
| RU2007146986A (ru) | 2009-06-27 |
| CA2607699A1 (fr) | 2006-12-07 |
| CR9512A (es) | 2008-04-16 |
| MX2007015056A (es) | 2008-03-11 |
| KR20080026562A (ko) | 2008-03-25 |
| US20100221250A1 (en) | 2010-09-02 |
| US20070036797A1 (en) | 2007-02-15 |
| AU2006252419A1 (en) | 2006-12-07 |
| AU2006252419B2 (en) | 2012-02-02 |
| IL187318A0 (en) | 2008-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR20C1061I2 (fr) | Anticorps anti-cd38 pour le traitement du cancer | |
| PH12018500062A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| MA30337B1 (fr) | Anticorps | |
| LUC00053I2 (fr) | Anticorps diriges contre cd38 pour le traitement du myelome multiple | |
| PH12020551153A1 (en) | Antibodies specific for cd70 and their uses | |
| TN2018000419A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof. | |
| MA67288A1 (fr) | Tubulysines et conjugués tubulysines-protéines | |
| MA29595B1 (fr) | Anticorps anti-cd40 humanises et procedes d'utilisation | |
| MA51669B1 (fr) | Modulateurs de tmem16a | |
| EP1885400A4 (fr) | Methodes de traitement des tumeurs du cerveau a l'aide d'anticorps | |
| CR7922A (es) | Inmunizacion activa para generar anticuerpos para beta-a- soluble | |
| EA200701299A1 (ru) | Производные стильбена и их применение для связывания и визуализации амилоидных бляшек | |
| ATE438411T1 (de) | Dosierung für die behandlung mit anti erbb2- antikörpern | |
| HUP0302589A2 (hu) | A béta-amiloid peptidet felismerő humanizált ellenanyagok | |
| PH12021552334A1 (en) | Antibodies to pyroglutamate amyloid-ã and uses thereof | |
| MA31886B1 (fr) | Anticorps anti-hepcidine et utilisations de ceux-ci | |
| ATE391503T1 (de) | Pyrazolidinon-verbindungen als liganden des ep2 und/oder ep4 prostaglandin-rezeptoren | |
| MA58646A1 (fr) | Tubulysines et conjugués tubulysines-protéines | |
| MA38161A1 (fr) | Anticorps anti-bmp-6 | |
| MA37670A1 (fr) | Anticorps anti-transglutaminase 2 | |
| MA27592A1 (fr) | Agonistes du recepteur du facteur de liberation 2 de la corticotropine. | |
| ATE392471T1 (de) | Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren | |
| MA53186B2 (fr) | Anticorps monoclonal qui se lie spécifiquement à cd20 | |
| MA49607A1 (fr) | Anticorps monoclonal pour il-5ra | |
| TN2010000108A1 (fr) | Traitement de symtomes vasomoteurs |